Mission Statement
To improve the cardiovascular health of patients by providing a forum for the review, exchange, and assimilation of findings from vascular biology research for dissemination to the clinical medicine community.
|
Background
VBWG was conceived in 1994 to unify the broad spectrum of vascular science that is driving the advances related to prevention and management of coronary artery disease. The VBWG serves as a forum for the periodic review, exchange, and assimilation of findings from vascular biology research for dissemination to the clinical medicine community. A key function of the Vascular Biology Working Group is to facilitate a consensus on what implications recent research findings have for present and future practices in patient care.
|
Disclaimer
The editorial content of this web site express the views of the individual contributors and does not necessarily reflect the views or recommendations of the University of Florida College of Medicine or the Foundation Sponsors. The indications and dosages of drugs discussed in these pages and discussions may vary from those approved by the Food and Drug Administration(FDA). The reader is advised to consult the full prescribing information for each medication prior to use.
|
Accreditation
The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
|
Program Chairman
Carl J. Pepine, MD, MACC
Eminent Scholar
American Heart Association - Suncoast Chapter Chair
Professor of Medicine
Chief, Division of Cardiovascular Medicine
University of Florida College of Medicine
Gainesville, Florida
Chairman, Vascular Biology Working Group
|
Program and CME Coordinator
Eileen Handberg, PhD, ARNP-BC
Associate Research Professor of Medicine
Director of Clinical Programs
Division of Cardiovascular Medicine
University of Florida College of Medicine
Gainesville, Florida
|
Educational Objectives
- To review new data on the pathophysiology of coronary artery disease and its relevance to treatment strategies and outcomes.
- To understand the pharmacologic and clinical rationale for various treatment options in the CAD patient.
- To develop a consensus on practical guidelines for day-to-day management of the coronary artery disease patient.
|
Funding
Provided through educational grants from AstraZeneca, Boehringer Ingelheim, CV Therapeutics, Inc., Daiichi Sankyo, Lilly, Merck & Co., Inc., Pfizer Inc, and sanofi-aventis.
|
Program Support Service
Educational support and implementation services for the VBWG, including this web site, are provided by Medical Education Consultants, LLC (MEDCON) of East Rutherford, NJ. For questions or more information contact info@medcononline.com.
|
|
About VBWG